Results 121 to 130 of about 5,232 (145)

The Effect of Concurrent Bronchodilator Therapy on the Efficacy and Safety of a Novel, Nebulized Glycopyrrolate in Phase 3 Studies in Subjects With Moderate to Very Severe COPD

Chest, 2017
Edward M Kerwin
exaly   +2 more sources

A34-04 Phase 2a, Randomized, Double-blind, Placebo-controlled Study of Inhaled Aero-007, a Novel Inhalation Solution Formulation of LABA and LAMA Combination (Indacaterol And Glycopyrrolate) for Nebulization Delivery in COPD

American Journal of Respiratory and Critical Care Medicine
Abstract Rationale Combination of a long-acting beta-agonist (LABA) bronchodilator and a long-acting muscarinic antagonist (LAMA) bronchodilator is the preferred choice for initial therapy for COPD patients with severe symptoms and/or with exacerbation risk.
A S Tutuncu, D Singh, J Patton, N A Hanania, F J Martinez   +4 more
openaire   +1 more source

Healthcare resource utilization and exacerbations in patients with chronic obstructive pulmonary disease treated with nebulized glycopyrrolate in the USA: a real-world data analysis

Journal of Medical Economics, 2021
Sanjay Sharma, Victoria Divino, Mitchell DeKoven   +2 more
exaly  

Dose-Ranging Study To Assess The Safety And Pharmacokinetic Profile Of Nebulized Glycopyrrolate (EP-101) Using High Efficiency Nebulizer In COPD Patients

B41. COPD: PHARMACOLOGICAL TREATMENT, 2012
Ahmet Tutuncu, Brian Leaker, Dave Singh
openaire   +1 more source

Faculty Opinions recommendation of Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2017
Ravi Kalhan, Sharon R Rosenberg
openaire   +1 more source

Exploratory Analysis of Exacerbation Incidence by Patient Subgroup in Three Phase 3 Trials of Nebulized Glycopyrrolate/eFlow CS

Chest, 2017
James Donohue, Robert Tosiello, Shahin Sanjar, Sanjay Sharma   +3 more
openaire   +1 more source

Cardiovascular Safety and Efficacy of Nebulized Glycopyrrolate/eFlow CS in Phase 3 Trials of Patients With Moderate to Very Severe COPD

Chest, 2017
Gary Ferguson, Robert Tosiello, Thomas Goodin   +2 more
openaire   +1 more source

Peak Inspiratory Flow Rate Baseline Measurements in Placebo-Controlled Phase 3 Studies of a Novel, Nebulized Glycopyrrolate Formulation

Chest, 2017
Barry Price, Shahin Sanjar, Robert Tosiello, Thomas Goodin   +3 more
openaire   +1 more source

The Impact of Missing Spirometry Data in the GOLDEN 3 and 4 Studies of Patients with Moderate-to-Very-Severe COPD Treated with Nebulized Glycopyrrolate

B64. COPD: MECHANISM AND TREATMENT, 2019
R. Tosiello, R. Claus, A. Ozol-Godfrey, K. Whicher, R. Carroll, G. Vega, T. Goodin   +6 more
openaire   +1 more source

Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials

Respiratory Medicine, 2017
Robert Tosiello, Edward M Kerwin, James F Donohue   +2 more
exaly